Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 9/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22615187 | 1.00 | HRH4 (0.58) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| SCHEMBL22615152 | 1.00 | HRH4 (0.58) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| Potassium Ion SCHEMBL29465405 | 0.91 | HRH4 (0.56) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| Potassium Ion SCHEMBL29465483 | 0.91 | HRH4 (0.56) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| SCHEMBL22615154 | 0.87 | HRH4 (0.55) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| SCHEMBL29465496 | 0.87 | HRH4 (0.55) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| SCHEMBL26835226 | 0.86 | HRH4 (0.58) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| SCHEMBL26814589 | 0.86 | HRH4 (0.56) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| SCHEMBL22615168 | 0.86 | HRH4 (0.51) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| SCHEMBL22615277 | 0.86 | HRH4 (0.51) | HRH4HRH3POLBSMN1; SMN2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3962909-B1 | NOVEL OXALYL PIPERAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO KG (DE) | 2023-10-04 | — | — | EP | disclosed |
| US-20220227737-A1 | NOVEL OXALYL PIPERAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-07-21 | — | — | US | disclosed |
| WO-2020221811-A1 | NOVEL OXALYL PIPERAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227737-A1 | NOVEL OXALYL PIPERAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, ZC3HAV1, MAVS | HRH4 3609/4885HRH3 3678/4885POLB 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.